

## **Payments to healthcare organisations reported by the medical device industry in Europe from 2017 to 2019: an observational study**

Authors: Dr. James Larkin<sup>1\*</sup>, Dr. Shai Mulinari<sup>2</sup>, Dr. Piotr Ozieranski<sup>3</sup>, Kevin Lynch<sup>4</sup>, Prof. Tom Fahey<sup>1</sup>, Dr. Akihiko Ozaki<sup>5,6</sup>, Dr. Frank Moriarty<sup>7</sup>

[\\*Larkinja@tcd.ie](mailto:Larkinja@tcd.ie)

1. Department of General Practice, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
2. Department of Sociology, Lunds Universitet, Lund, Sweden
3. Department of Social and Policy Sciences, Centre for the Analysis of Social Policy, University of Bath, Bath, UK
4. Unaffiliated
5. Department of Breast and Thyroid Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Fukushima, Japan
6. Medical Governance Research Institute, Tokyo, Japan
7. School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland;

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## **Abstract**

### **Background**

Medical device industry payments to healthcare organisations (HCOs) can create conflicts of interest which can undermine patient care. One way of addressing this concern is by enhancing transparency of industry financial support to HCOs. MedTech Europe, a medical device trade body, operate a system of disclosure of education payments to European HCOs. This study aimed to characterise payments reported in this database and to evaluate the disclosure system.

### **Methods**

An observational study of education-related payments to HCOs reported by the medical device industry in Europe was conducted. Data was manually extracted from [transparentmedtech.eu](https://transparentmedtech.eu). The primary outcome variable is the value of the payments, overall, and for each year, payment type, and country. The accessibility, availability and quality of the database was also analysed, using a proforma with 15 measures.

### **Findings**

Overall, 116 medical device companies reported education-related payments in 53 countries, valuing over €420 million between 2017-2019, increasing in value between 2017-2019, from €91,289,672 to €175,414,302. Ten countries accounted for 94% of all payments and ten companies accounted for 80% of all payments. The accessibility, availability and quality of the database, rated low for six measures, medium for six measures and high for three measures.

### **Interpretation**

There is a large amount of education-related payments from medical device companies to European HCOs, creating substantial potential for conflicts of interest. MedTech Europe's disclosure system has many shortcomings. A European-wide publicly mandated disclosure system for both the medical device and pharmaceutical industries should be introduced.

### **Funding**

Swedish Research Council (SM, PO)

### **Keywords**

Conflicts of interest; Education; Medical device companies; Medical devices; Medical education; Payment; Pharmaceutical companies; Physician Payments Sunshine Act; Physician payment; Physician reporting; health policy; Disclosures; Transparency; Self-regulation

## Introduction

Each year, billions of euro are paid by medical device and pharmaceutical companies to healthcare professionals (HCPs) and healthcare organisations (HCOs), ostensibly for research, consultancy and for HCPs' education, among other areas.<sup>1-5</sup> The medical device industry accounts for a large proportion of this, with some estimating that they make up the majority of industry payments.<sup>1</sup> Medical devices are a vital component for health systems, used for diagnosis, treatment, and as aids to everyday activities.<sup>6</sup> Despite this, the vast majority of research has been devoted to examining the patterns, nature and effects of pharmaceutical industry payments to HCOs and HCPs.<sup>2-5</sup> Payments from industry to HCPs and HCOs can create conflicts of interest.<sup>7</sup> Extensive evidence shows that receipt of payments from the pharmaceutical industry is associated with higher prescribing rates, higher prescribing costs, and lower prescribing quality.<sup>8-10</sup> Recent research suggests that similar issues may exist for payments associated with medical devices.<sup>11,12</sup> For example, a 2020 study showed that US physicians' choice of medical device is associated with medical device industry payments.<sup>11</sup> Some medical device industry payments have also been associated with legal breaches, for example of the US Anti-Kickback Statute which prohibits directly or indirectly offering or paying anything of value to induce physicians to procure certain medical products, such as devices, under state programs.<sup>13</sup>

To start addressing these issues, some countries, such as the United States and France, have introduced a legal requirement for disclosure of payments by industry to HCPs and HCOs.<sup>14</sup> However, the preferred approach among European countries is industry self-regulation, which is based on codes of practice developed and implemented by industry trade associations, rather than legal requirements.<sup>14</sup> As part of this, industry bodies have implemented self-governed systems of disclosure for payments to HCPs and HCOs; such systems are associated with a range of limitations, such as poor accessibility and limited levels of disclosure.<sup>14</sup> In Europe, there is a growing amount of research on industry payments to HCPs and HCOs, but it almost exclusively focusses on the pharmaceutical industry.<sup>4,5,8,14-17</sup> This study is, to our knowledge, the first European and multi-country study of medical device industry payments to healthcare organisations.

The importance of this research is highlighted by the recent implementation of the European Medical Devices Regulation, which aims to promote transparency in the medical device industry through the establishment of a comprehensive EU database on medical devices.<sup>18</sup> However, when it comes to the disclosure of payments made by the medical device industry, it is MedTech Europe, the primary trade association for the European medical device industry, that oversees and regulates the European transparency.

## **Policy Background**

In January 2023, 137 companies were members of MedTech Europe.<sup>19</sup> However, there are many medical device companies who are not members of MedTech Europe. For example, a 2015 article estimated that less than 10% of medical device companies operating in the UK were members of the Association of British Healthcare Industries, which is a member of MedTech Europe. Examples of MedTech Europe member companies include Roche, Medtronic and Abbott.<sup>19</sup> Notably, several member companies have large pharmaceutical portfolios, such as Johnson and Johnson<sup>20</sup> and Baxter.<sup>21</sup>

MedTech Europe has implemented a code of practice for their member companies to disclose details of ‘educational grants’ on a website ([www.transparentmedtech.eu](http://www.transparentmedtech.eu)).<sup>22,23</sup> These educational grants are described by MedTech Europe as supporting “Healthcare Professionals’ independent Medical Education”, though they also include grants for ‘public awareness campaigns’ as well as scholarships and fellowships.<sup>22</sup> The MedTech Europe disclosure website, [www.transparentmedtech.eu](http://www.transparentmedtech.eu), requires member companies to report education related payments to HCOs registered in member countries of the European Free Trade Area (Switzerland, Norway, Liechtenstein and Iceland), the United Kingdom, Russia, Turkey and the European Union.<sup>23</sup> A Europe-wide database is in contrast to the approach of the European Federation of Pharmaceutical Industries and Associations (EFPIA) which allows each European country to set up its own disclosure system.<sup>14</sup> However, it should be noted that there are exceptions for four EU countries (Belgium, France, the Netherlands and Portugal), because, in those countries, the MedTech Europe disclosure website is superseded by local laws.<sup>23</sup>

Publications on the [transparentmedtech.eu](http://transparentmedtech.eu) website began in 2018, for payments made in 2017.<sup>24</sup> Only payments to HCOs are reported. According to the MedTech Europe definition, HCOs include hospitals, clinics, laboratories, pharmacies, research institutions, foundations, universities and professional societies (full definition in Appendix Box 1). Notably, patient organisations are excluded from the MedTech Europe definition of HCOs. For the definition of medical devices used by MedTech Europe see Appendix Box 2. In 2018 MedTech Europe introduced a rule that member companies could no longer make payments directly to healthcare professionals for third party organised events; instead payments would be made to HCOs such as hospitals or professional societies, acting as intermediaries, who would then disburse the payments to HCPs.<sup>22</sup>

## **Aim and objectives**

Overall, a Europe-wide database offers a unique opportunity to understand the scale of payments made by the medical device industry to healthcare organisations in Europe, and to inform the

development of regulation in this area. To achieve this, the aim of the study is to characterise payments reported in the *MedTech Europe* database from medical device companies to HCOs from 2017 to 2019 and to evaluate the system of disclosure itself.

## Methods

This is an observational study of payments to HCOs reported by the medical device industry in Europe. It includes annual data from 2017 to 2019 provided by medical device companies who are members of MedTech Europe. A protocol was registered for this study in February 2022.<sup>25</sup> Details of deviations from the protocol are in Appendix Box 3.

### Database overview

The MedTech Europe disclosure website contains data on two categories of payments: 1) *support to educational events* and 2) *other educational grants*. Definitions are not provided for these categories but examples are. Educational events include ‘Support for HCP Participation at Third Party Organised Educational Events’ and other educational grants include ‘Scholarships, Fellowships and/or Grants for Public Awareness Campaigns’ as well as educational grants to support general medical education topics. Payments to HCOs are supposed to be aggregated on a year/donation-type basis – for example all payments under ‘other educational grants’ in 2017 by one medical device company to one HCO should be included in a single entry, though there were multiple examples of this not being adhered to

### Data extraction and processing

A data extraction form was developed in Microsoft Excel, capturing details of medical device company, year of payment, recipient identifying details (HCO name and country of registration) and payment value. Data was manually extracted from [www.transparentmedtech.eu](http://www.transparentmedtech.eu), via an exhaustive search (details in Appendix Box 4).

In some instances, medical device company subsidiaries or affiliates reported separately from their parent company on the [transparentmedtech.eu](http://transparentmedtech.eu) website. For analysis purposes, these companies were merged (Appendix Table 1). To determine the relationship between reporting companies the following information was used: 1) The contact email address provided by the reporting entity on the website and 2) the parent company’s website and where available the subsidiary/affiliate’s website.

All payments were exchanged to euro using the average annual exchange rates for the respective year published by the European Central Bank.<sup>26</sup> The euro value of all totals were rounded to the nearest euro. MedTech Europe stipulate that all payments should be exclusive of VAT.<sup>22</sup> Three entries totalling €14,000 were removed from 2017 for ‘Other Educational Grants’ because the recipient was ‘TEST’.

## **Outcome variables**

The primary outcome variable is the value of the payments, overall, and for each year, payment type, and country. A range of secondary outcomes are also included. Number of unique entries was also analysed for each year, payment type, and country. Gini coefficients are used as a measure of concentration of payments across all countries and companies. A Gini coefficient is a measure of inequality that can range from 0-1 where 1 would represent perfect inequality (e.g. one company accounting for the full value of all payments) and 0 (all companies making the same value of payments) would represent perfect equality.

The ten countries, companies and HCOs with the highest total payment value accounted for a significant proportion of the overall total value of payments. Therefore, additional secondary outcome variables are included for them. Gini coefficients are used across countries within each of the top 10 companies and across medical device companies within each of the top 10 countries. For each of the top 10 countries, companies and HCOs, the percentage of the total value of payments accounted for by each country, company or HCO was included. For each of the top ten countries, outcome variables also include: the total value of payments per 1,000 population, and the number of medical device companies reporting payments in that country. Population figures for payments per 1,000 population and Gini coefficient calculations were gathered for 2019 only, from Eurostat<sup>27</sup> and World Bank data.<sup>28</sup> For Gini coefficients, population figures are needed in order to understand what would have been a proportional payment value for a country. For each of the top ten companies, outcome variables also include the number of countries where payment recipients are located. For the top ten HCOs, outcome variables also include: number of companies each HCO was in receipt of payments from, the company with the greatest value of payments to each HCO, and the country the HCO is registered in.

Background information of the 10 medical device companies who made the highest total value of payments are provided in Appendix Table 2. This includes details of the medical device areas in which each company makes the greatest amount of revenue, the overall revenue of the companies, and their research and development expenditure. Information was gathered using each company's annual report for 2019 and the MedTech Europe website.<sup>29</sup>

The accessibility, availability and quality of the database is also included as a secondary outcome. This was assessed using an adapted version of the proforma developed by Ozieranski and colleagues to examine the accessibility and quality of pharmaceutical industry payment data.<sup>14</sup> Several changes were made to the proforma to provide a more comprehensive assessment of the disclosure system (details of the changes can be seen in Appendix Box 5). The proforma contains 15 measures, nine

measures of accessibility, three measures of availability and three measures of quality. The measures can be rated at one of three levels from low to high, for seven of the measures there are only two levels, low and high. The full proforma can be seen in Appendix Table 3. Other issues with the database that were not covered in the proforma assessment were inductively assessed, with further details of analysis methods detailed below.

### **Quantitative analysis**

Payment values are summarised using totals, means and standard deviations, and medians and interquartile ranges. Number of unique entries is summarised using totals.

For the calculation of Gini coefficients for countries overall and for the countries within each of the top 10 companies, only MedTech Europe member countries who do not have national laws that supersede industry body guidance were included.

For analysis of HCOs, naming was inconsistent, so detailed analysis was not possible. Analysis was conducted for the top 10 HCOs only, based on of their names as reported. Quantitative analysis was conducted using R-4.1.1 software.

### **Content Analysis**

For analysis of the accessibility, availability and quality of the database, data was coded by one author (JL) and cross-checked by a second author (FM). During the process of data extraction, analysis and database assessment, a content analysis was conducted to document any other issues with the database that had not been included in the assessment of the accessibility, availability and quality of the database. This was conducted by one author (JL) and cross-checked by a second (SM or FM).



## Results

### Payment Patterns Overall

In total, 116 medical device companies reported payments valuing €420,560,631 between 2017-2019. Increasing from €91,289,672 in 2017 to €175,414,302 in 2019, a 92% increase. The number of companies reporting payments in each year also increased, from 66 in 2017 to 101 in 2018 and 94 in 2019 a 42% increase between 2017 and 2019. The dominant payment category in each year was *Support to Educational Events* (between 75.5% and 84.8% annually). However, *Other Educational Grants* showed a higher overall increase (15.2% of all payments in 2017 vs 24.5% in 2019). More details can be found in table 1.

Table 1. Payments broken down by payment type

	2017	2018	2019	Total
<i>Overall spending (% of total)</i>				
Support to Educational Events	€77,428,198 (84.8%)	€122,768,363 (79.8%)	€132,400,996 (75.5%)	€332,597,557 (79.1%)
Other Educational Grants	€13,861,474 (15.2%)	€31,088,294 (20.2%)	€43,013,306 (24.5%)	€87,963,074 (20.9%)
Total	€91,289,672	€153,856,657	€175,414,302	€420,560,631
<i>Value (€) per entry, mean (SD)</i>				
Support to Educational Events	20,116 (694,978)	14,676 (544,128)	15,635 (541,871)	16,082 (574,305)
Other Educational Grants	15,557 (27,334)	23,659 (85,867)	19,288 (148,074)	19,834 (115,602)
Overall	19,259 (626,361)	15,896 (506,839)	16,397 (486,809)	16,744 (523,399)
<i>Value (€) per entry, median (IQR)</i>				
Support to Educational Events	2,349 (1,000-6140)	2,008 (888-6,140)	2,000 (810-5,320)	2,013 (870-5,502)
Other Educational Grants	4,900 (1,495-20,000)	5,355 (1,656-21,784)	2,579 (733-11,000)	3,676 (1,038-16,000)
Overall	2,500 (1,000-7,898)	2,263 (948-6,292)	2,039 (800-6,000)	2,238 (900-6,500)
<i>Number of unique entries (% of total)</i>				
Support to Educational Events	3,849 (81.2%)	8,365 (86.4%)	8,468 (79.2%)	20,682 (82.3%)
Other Educational Grants	891 (18.8%)	1,314 (13.6%)	2,230 (20.8%)	4,435 (17.7%)
Overall	4,740	9,679	10,698	25,117

### Countries

In total, payments were reported in 53 countries (Appendix Tables 4 & 5). Notably, payments were reported in the four countries with superseding national legislation; €21,471,896 in the Netherlands, €119,387 in Portugal, €2,176,609 in France and €1,517,567 in Belgium (Appendix Table 4). Also, €431,623 in payments was reported in 28 countries that were not members of MedTech Europe (Appendix Table 4).

However, 10 countries made up 93.8% of the total value of payments (Table 2). Switzerland made up 42.0% of the total value of payments, followed by Spain (20.3%). Notably, there is a very high concentration of payments in Switzerland, where across the 54 medical device companies making payments, the Gini coefficient was 0.96, compared to 0.78 for Spain. The Gini coefficient for the 28 countries without superseding national legislation was 0.72. When examining euros paid per 1,000 population, Switzerland remains by far the highest recipient (€20,661). One other notable country with very high levels of euros paid per 1,000 population is Luxembourg with €2,148 (Appendix Table 5). Croatia, Slovenia and Ireland also have high levels of euros paid per 1,000 population, all with over €400 per 1,000 population (Appendix Table 5). The three countries with the lowest levels of

euros paid per 1,000 population were Cyprus, Bulgaria and Romania, all with less than €25 per 1,000 population (Appendix Table 5).

Table 2. Ten countries with highest value of reported payments to healthcare organisations between 2017-2019

	Country	Support to Educational Events	Other Educational Grants	Total value of payments (€)	€ per 1,000 population	% of the total value of payments accounted for by each country	Number of medical device companies reporting payments	Gini Coefficient for Companies within Country*
1	Switzerland	165,872,384	10,623,301	176,495,685	20,661	42.0	54	0.96
2	Spain	61,850,963	23,317,944	85,168,908	1,815	20.3	82	0.78
3	UK	18,695,575	17,860,467	36,556,042	549	8.7	67	0.82
4	Italy	24,302,166	6,172,585	30,474,751	505	7.2	57	0.74
5	Netherlands	7,346,538	14,125,358	21,471,896	1,242	5.1	38	0.83
6	Germany	16,712,991	4,310,364	21,023,355	253	5.0	56	0.79
7	Austria	6,104,074	3,044,929	9,149,003	1,033	2.2	47	0.80
8	Poland	5,007,723	539,482	5,547,206	146	1.3	36	0.75
9	Turkey	3,436,760	1,058,739	4,495,499	55	1.1	20	0.64
10	Russia	2,742,170	1,571,552	4,313,722	30	1.0	18	0.61




Figure 1. Payments (€) per 1,000 population across member countries without superseding laws from 2017 to 2019

## **Companies**

Of the 116 medical device companies who reported payments between 2017-2019 (Appendix Table 1), ten companies made up 80.0% of payments (Table 3). The overall Gini coefficient for the concentration of medical device company payments to HCOs was 0.89. This high degree of concentration was largely driven by one medical device company, Johnson & Johnson Medical, who accounted for 43.4% of all payments. Johnson & Johnson Medical themselves also had a very high concentration of payments across countries; across the 26 member countries without superseding legislation, the Gini coefficient was 0.90, explained by its large investment in Switzerland, compared to 0.46 for Abbott Laboratories. Another notable element of the top 10 companies is that Medtronic International Trading Sàrl only disclosed payments in 2017 and 2018.

With regard to the type of companies in the top 10, two are involved in in-vitro diagnostic medical devices and medical devices (refer to Appendix Box 2 for distinction), and 7 are involved in medical devices only. Considering the top three product areas per company by revenue, three of top ten had cardiac rhythm management, three had orthopaedics and three had surgery. Full overviews of the top ten companies are provided in Appendix Table 2.

Table 3. Ten medical device companies with highest value of payments disclosed between 2017-2019

	Company	Support to Educational Events	Other Educational Grants	Total value of payments (€)	% of the total value of payments accounted for by each company	Number of countries where payment recipients are located	Gini Coefficient for Countries within Companies*
1	Johnson & Johnson Medical	171,370,841	11,318,575	182,689,416	43.4	27 (26 eligible)	0.90
2	Abbott Laboratories	30,348,508	13,293,670	43,642,178	10.4	31 (24 eligible)	0.46
3	Boston Scientific	19,767,471	13,369,855	33,137,326	7.9	26 (20 eligible)	0.52
4	Medtronic International Trading Sàrl	18,160,048	5,594,744	23,754,792	5.6	29 (26 eligible)	0.58
5	Baxter	6,807,381	9,220,650	16,028,031	3.8	23 (21 eligible)	0.82
6	Carl Zeiss Meditec Iberia	7,998,571	0	7,998,571	1.9	1 (1 eligible)	N.A.
7	Smith & Nephew Orthopaedics AG	3,291,518	4,304,874	7,596,393	1.8	31 (15 eligible)	0.25
8	BIOTRONIK	4,082,339	3,403,986	7,486,324	1.8	18 (14 eligible)	0.68
9	Roche	4,169,433	3,198,437	7,367,869	1.8	27 (24 eligible)	0.20
10	Zimmer GmbH	1,934,888	5,036,747	6,971,635	1.7	20 (17 eligible)	0.59

### Healthcare organisations

There were 13,916 uniquely named HCOs who received at least one payment between 2017 and 2019. However, this likely includes many cases of the same HCO being included with a different spelling or a different name. The top 10 HCOs are shown in Table 4. AO Technology in Switzerland was in receipt of 36% of all payments, representing approximately €151.5 million, all of which was from Johnson and Johnson Medical, for *Support to Educational Events*. Another notable entry is ‘European HCO and PCO’ which is in receipt of the third largest amount. However, this is likely to be an aggregation of several payments to different HCOs and professional conference organisers by B. Braun. Notably, seven of the top ten recipients each received all of their payments from single

companies. Also, of note, six of the top ten companies are registered in Spain and the other four are registered in either Germany or Switzerland.

Table 4. Ten named recipients with highest value of payments received between 2017-2019\*

	Healthcare organisation	Support to Educational Events	Other Educational Grants	Total value of payments (€)	Number of companies in receipt of payments from	Company with greatest value of payments to HCO	% of the total value of payments accounted for by each company	Country
1	AO Foundation**	151,486,352	0	151,486,352	1	Johnson & Johnson Medical	36.0	Switzerland
2	Sociedad Española De Enfermería Nefrológica	43,000	6,651,587	6,694,587	1	Baxter	1.6	Spain
3	European HCO and PCO	2,847,655	0	2,847,655	1	B. Braun	0.7	Germany
4	Fundacion para la Investigacion en Gastroenterologica y Hepatologia	12,000	2,479,520	2,491,520	1	Boston Scientific	0.6	Spain
5	Osteosynthesis and Trauma Care Foundation	2,349,603	0	2,349,603	1	Stryker	0.6	Switzerland
6	Nubbecas Focused Solutions For Companies	2,087,273	0	2,087,273	1	Baxter	0.5	Spain
7	CME4U GMBH	1,991,401	30,376	2,021,777	6	Boston Scientific	0.5	Germany
8	Fundacion Fidis	1,591,598	6,700	1,598,298	1	Baxter	0.4	Spain
9	Fundacion Senefro	259,056	1,307,822	1,566,878	4	Baxter	0.3	Spain
10	Avoris Retail Division S.L.	1,407,407	0	1,407,407	3	Coloplast	0.3	Spain

### Accessibility, Availability and Quality of the Database

Overall, using the 15 measures of accessibility, availability and quality, the database rated low on six measures, medium on six measures and high on three measures. The three areas where the database rated high were 1) the database format was a website as opposed to individual PDFs, 2) structure; all companies follow a single template, and 3) clear tax reporting; VAT is excluded for all entries. The six areas where the database rated low were 1) availability of customisable summary statistics, 2) downloadability, 3) removal of data after certain number of years, 4) breadth of recipients, 5) breadth of donors, and 6) payment areas did not include research, consulting, gifts, and charitable donations. For more details see Appendix Table 3. Other issues with the database that were inductively noted included 1) itemisation of payments, contrary to guidance<sup>22</sup> 2) disclosure



of payments to patient organisations and individual HCPs, contrary to guidance<sup>22</sup> and 3) instances of payments disclosed on the [transparentmedtech.eu](https://transparentmedtech.eu) website but not the respective mandatory disclosure system. Full details are included in Appendix Box 6.

## Discussion

### Summary

Between 2017 and 2019 medical device companies disclosed €420 million in educational grants to healthcare organisations creating a large potential for conflicts of interest. These payments were made by 116 medical device companies to HCOs registered in 53 countries. Eighty percent of payments were accounted for by the top 10 companies, and Johnson and Johnson Medical accounted for 43% of payments which were primarily to one healthcare organisation, AO Foundation in Switzerland. Seventy-nine percent of the €420 million in educational grants were for HCP participation at third party organised educational events, and the other 21% was for scholarships, fellowships, educational grants to support general medical education topics or for public awareness campaigns. The database was rated as low for six measures of accessibility, availability and quality, medium for six measures and high for three measures, indicating major shortcomings with this system of disclosure.

### Results in Context

Unlike in the legally-mandated US Open Payments database, no information is provided on the therapeutic area or device or test that each payment relates to. However, the examination of the top recipients, who account for 42% of all payments, provides an opportunity to understand what areas the payments relate to. AO foundation is the largest recipient. This HCO hosts educational events for surgeons, in the areas of 'trauma and disorders of the musculoskeletal system.'<sup>30</sup> The fifth highest recipient, Osteosynthesis and Trauma Care Foundation, is also a HCO with a focus on orthopaedics.<sup>31</sup> Two of the top ten are nephrology HCOs. However, several of the top ten HCOs appear to be event organisers or travel companies (e.g. Nubbecas Focused Solutions For Companies,<sup>32</sup> CME4U GMBH,<sup>33</sup> Avoris Retail Division S.L.<sup>34</sup>) making it difficult to know what healthcare areas their payments relate to. In terms of product areas that generated the most revenue for the top ten medical device companies: cardiology, orthopaedics, and surgery appeared the most frequently. These areas are similar to four of the top five payment areas in the US for medical devices.<sup>1</sup>

In terms of the countries HCOs are registered in, two of the top ten are based in Switzerland; AO Foundation and Osteosynthesis and Trauma Care Foundation. However, both organisations appear to hold events in multiple countries.<sup>30,31</sup> If payments registered for Switzerland are actually used in other countries, it partly undermines the validity of the database. Six of the top ten companies are registered in Spain, and for at least three of these companies,<sup>35-37</sup> their activities appear to be primarily in Spain. Given this information, along with the fact that Spain is one of the highest recipients of payments, it implies that industry marketing activities might be especially prominent

there. This is reinforced by a recent study of the pharmaceutical industry which found that Spain stood out in a seven-country comparison because of its higher payment amounts.<sup>4</sup> There are a few countries with relatively low payments, like Romania, Cyprus and Bulgaria. The reasons for such large disparities between countries are unclear but may include, among other reasons, culture, demographics, regulations, the organisation of healthcare and national association compliance.<sup>38</sup> Further research is needed to elucidate these issues.

Also of note is the large amount of payments reported in countries with separate mandatory reporting systems (Belgium, France, Netherlands and Portugal). For example, €21 million in payments were declared in the Netherlands. This creates confusion as it is unclear whether these payments were or were not also reported via the national mandatory disclosure systems. As noted in the content analysis, there are several cases of payments disclosed on the [transparentmedtech.eu](https://transparentmedtech.eu) website but not the respective mandatory disclosure system.

In terms of the concentration of payments, there was a similar Gini coefficient for UK pharmaceutical companies; 0.85<sup>5</sup> compared to 0.89 for European medical device companies, demonstrating the dominance of a few companies. Also, the large concentration of payments amongst the top ten medical device companies is similar to the top ten pharmaceutical companies making payments to HCOs in the UK. In the UK, the top ten companies made up 82% of the total value of payments,<sup>5</sup> compared to 80% for medical device companies in Europe.

Overall, the figure of €420 million likely underestimates the true extent of medical device industry payments. Firstly, the large increase in payments between 2017 and 2018 is very likely a function of the rule introduced in 2018 that member companies could no longer make payments directly to healthcare professionals for attendance at third party organised educational events. Instead payments would be made to HCOs such as hospitals or professional societies, acting as intermediaries, who would then make the payments to healthcare professionals.<sup>22</sup> Therefore, the 2017 figure is likely a large underestimate of the value of educational grants provided. Secondly, it should be noted that according to MedTech Europe, in 2019, 5% of MedTech Europe national associations had not banned their member companies from providing direct sponsorship of healthcare professionals.<sup>38</sup> So the figures for 2018 and 2019 are also likely to be underestimates. Thirdly, it is not clear whether all medical device companies are reporting all relevant payments. For example, Medtronic reported no payments in 2019 despite disclosing payments of almost €24 million across 2017 and 2018. This may be as a result of no payments being made or alternatively no disclosure being submitted to [transparentmedtech.eu](https://transparentmedtech.eu). Like self-regulatory codes for the pharmaceutical industry,<sup>17</sup> MedTech Europe does not appear to require member companies to make

a report if they have not made payment in a given year. Under-reporting has been documented in other self-regulatory systems.<sup>15,16</sup> Finally, many companies are not members of MedTech Europe or the national associations within MedTech Europe,<sup>39</sup> which is likely to also lead to large underestimates of payments. This is a consistent problem with systems that employ self-regulation.<sup>17</sup>

In terms of accessibility and quality of the database, its general low rating was similar to the rating of the few existing pharmaceutical industry disclosure databases in European countries, most of which are also not downloadable, do not use unique identifiers consistently, and do not make customisable summary statistics available.<sup>14</sup> The two areas that transparentmedtech.eu scored medium or high, where most pharmaceutical industry disclosure systems scored low,<sup>14</sup> were availability of a limited search function and clarity of tax inclusion, respectively.

A major limitation is the narrow breadth of payments covered by the database, far more limited than most pharmaceutical industry databases, be they publicly mandated or self-regulatory.<sup>14</sup> It should be noted that Eucomed, a representative body for European medical device companies which is now part of MedTech Europe,<sup>40</sup> previously considered disclosing payments that covered areas other than education, these included 1) Consultancy fees and expenses related to consultancy, 2) Charitable donations, 3) Research grants, and 4) Gifts and give-aways.<sup>41</sup> Also, many pharmaceutical industry disclosure websites disclose research and development payments to healthcare professionals and healthcare organisations, and these make up a large proportion of payments (though in Europe this is usually presented as an aggregated value for each company).<sup>42</sup>

Nonetheless, these areas are not covered by the transparentmedtech.eu database.<sup>22</sup> Another major area that is not covered by transparentmedtech.eu, but is covered by US Open Payments, is ownership or shares in medical device companies.<sup>22,43</sup> Wider coverage of payments is very important, as several of these non-covered areas (e.g. consulting payments) have been found, on occasion, to be used for improper payments to physicians.<sup>44</sup> The limited breadth of payment areas along with the other shortcomings discussed above may be the primary reason for the large differences between the payment levels found in this research, compared to those found in studies of the UK pharmaceutical industry and the US medical device industry. Pharmaceutical companies reporting payments on the self-regulatory disclosure website for the British pharmaceutical industry<sup>45</sup> made payments to HCOs and HCPs registered in the UK valuing €2.96 billion between 2017 and 2019,<sup>46</sup> compared to the €36.6 million reported by medical device companies to UK HCOs on transparentmedtech.eu. In the US, medical device companies pay about \$904 million annually, just to physicians.<sup>1</sup>

Overall, the usefulness of the database is severely limited, and it does not provide transparency on the true scale of payments. Given the deficiencies, there does not appear to be a clear intended user or audience for the database. Like other self-regulated disclosure systems, it may instead be a means of creating an appearance of credibility and compliance in order to avoid regulation of the industry's marketing activities.<sup>47</sup>

### **Strengths and limitations**

A major strength of this study is the large number of countries, companies covered, 53 and 116 respectively. Also, this is the first Europe-wide analysis of medical device industry payments to HCOs. Another strength of this study was the analysis of data over a three-year period. A further strength of this study is the advancement of the database assessment tool developed by Ozieranski and colleagues.<sup>14</sup>

A limitation is the lack of analysis of HCOs. This was due to the inconsistent use of unique identifiers by medical device companies when reporting payments. Also, the inability to download the database meant that manual data extraction was conducted which may have led to errors. Many of the other limitations with the study are associated with the accessibility, quality and availability of the data itself, discussed above.

### **Implications**

This research adds to the extensive literature documenting the shortcomings of self-regulated disclosure systems for industry payments to HCPs and HCOs.<sup>2,3,5,14,48</sup> Overall the shortcomings of this database are reflective of general issues seen with self-regulation across several industries, such as pharmaceutical,<sup>49,50</sup> nutrition<sup>51</sup> and alcohol.<sup>52</sup> This highlights the need for a publicly mandated database. This could be EU wide and cover both the medical device and pharmaceutical industry. Several groups have suggested harmonisation of minimum standards for transparency across Europe, which would include a high-quality pan-European database.<sup>14,17</sup> The database could be downloadable, cover a broad range of payments to healthcare professionals, HCOs and patient organisations, and provide information on the therapeutic area and device or test that each payment relates to in ways that allow integration with the planned EU database on medical devices.<sup>18</sup>

The main implication of this study is the large potential for conflicts of interest in European healthcare arising from the large value of the payments (at least €420 million) being made by the medical device industry to HCOs related to education. These payments provide medical device companies with an opportunity to influence a range of HCOs such as hospitals, universities, clinical societies and professional training bodies, all of which have a significant influence on healthcare

practice. There is extensive evidence suggesting that payments of this nature have a negative influence on pharmaceutical prescribing.<sup>8-10</sup> There is some evidence that these payments are associated with sub-optimal medical device procurement in the USA,<sup>11,12</sup> though more research is needed in this area to understand the relationship between medical device industry interaction and clinical practice across countries.

As pointed out in a seminal US Institute of Medicine report: ‘The disclosure of individual and institutional financial relationships is a critical but limited first step in the process of identifying and responding to conflicts of interest.’<sup>7</sup> Many have called for greater restrictions in the relationship between industry and physicians/HCOs.<sup>7,53,54</sup> However, restrictions around education may create a funding gap. Alternative funding sources such as state funding, a hypothecated medical device industry tax,<sup>49</sup> or HCPs paying for education using their own personal income, could be considered.

### **Conclusion**

This study shows the large amount of payments made by the medical device industry to healthcare organisations in 53 countries, primarily in Europe. While this provides a first estimate of the scale of payments, the major shortcomings with the database and the reporting requirements make it likely that the total value of payments is significantly larger. An EU mandated system of disclosure for the medical device and pharmaceutical industries could address these shortcomings, and enhance transparency in the healthcare sector’s interactions with industry. However, greater transparency is just one step in addressing the potential negative effects that industry payments to healthcare organisations can have on healthcare.

**CREDIT Statement:**

James Larkin: conceptualisation, data curation, formal analysis, methodology, writing – original draft

Shai Mulinari: formal analysis, methodology, writing – review & editing

Piotr Ozieranski: methodology, writing – review & editing.

Kevin Lynch: investigation, writing – review & editing.

Tom Fahey: conceptualisation, writing – review & editing.

Akihiko Ozaki: writing – review & editing.

Frank Moriarty: conceptualisation, formal analysis, visualisation, writing – review & editing.

**Funding Statement:**

JL, KL, TF, AO and FM received no specific funding associated with this publication. SM and PO were supported by the grant 'Following the money: cross-national study of pharmaceutical industry payments to medical associations and patient organisations', awarded by The Swedish Research Council (VR), no. 2020–01822. The funder had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the articles; and in the decision to submit it for publication.

## References

1. Bergman A, Grennan M, Swanson A. Medical Device Firm Payments To Physicians Exceed What Drug Companies Pay Physicians, Target Surgical Specialists: Study examines payments medical device firms pay to physicians. *Health Affairs*. 2021;40(4):603-612.
2. Moriarty F, Larkin J, Fahey T. Payments reported by the pharmaceutical industry in Ireland from 2015 to 2019: An observational study. *Health Policy*. 2021;125(10):1297-1304.
3. Ozaki A, Saito H, Senoo Y, et al. Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: analysis of payment data in 2016. *Health Policy*. 2020;124(7):727-735.
4. Mulinari S, Martinon L, Jachiet P-A, Ozieranski P. Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries. *Health Policy*. 2021;
5. Ozieranski P, Csanadi M, Rickard E, Tchilingirian J, Mulinari S. Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015. *JAMA Netw Open*. Jun 5 2019;2(6):e196253. doi:10.1001/jamanetworkopen.2019.6253
6. World Health Organization. Medical devices. Accessed 18 January, 2022. [https://www.who.int/health-topics/medical-devices#tab=tab\\_1](https://www.who.int/health-topics/medical-devices#tab=tab_1)
7. Institute of Medicine Committee on Conflict of Interest in Medical Research E, Practice. The National Academies Collection: Reports funded by National Institutes of Health. In: Lo B, Field MJ, eds. *Conflict of Interest in Medical Research, Education, and Practice*. National Academies Press (US); 2009.
8. Goupil B, Balusson F, Naudet F, et al. Association between gifts from pharmaceutical companies to French general practitioners and their drug prescribing patterns in 2016: retrospective study using the French Transparency in Healthcare and National Health Data System databases. *Bmj*. 2019;367
9. Brax H, Fadlallah R, Al-Khaled L, et al. Association between physicians' interaction with pharmaceutical companies and their clinical practices: A systematic review and meta-analysis. *PloS one*. 2017;12(4):e0175493.
10. Hartung DM, Johnston K, Cohen DM, Nguyen T, Deodhar A, Bourdette DN. Industry payments to physician specialists who prescribe repository corticotropin. *JAMA network open*. 2018;1(2):e180482-e180482.
11. Annappureddy AR, Henien S, Wang Y, et al. Association between industry payments to physicians and device selection in ICD implantation. *Jama*. 2020;324(17):1755-1764.
12. Bergman A, Grennan M, Swanson A. *Lobbying physicians: Payments from industry and hospital procurement of medical devices*. 2021.
13. The United States Department of Justice. False Claims Act Settlements and Judgments Exceed \$2 Billion in Fiscal Year 2022. Accessed 18 April, 2023. <https://www.justice.gov/opa/pr/false-claims-act-settlements-and-judgments-exceed-2-billion-fiscal-year-2022>
14. Ozieranski P, Martinon L, Jachiet P-A, Mulinari S. Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review. *BMJ open*. 2021;11(12):e053138.
15. Ozieranski P, Csanádi M, Rickard E, Mulinari S. Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016). *BMJ Open*. Sep 19 2020;10(9):e037351. doi:10.1136/bmjopen-2020-037351
16. Rickard E, Ozieranski P, Mulinari S. Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK. *Health Policy*. Dec 2019;123(12):1244-1250. doi:10.1016/j.healthpol.2019.08.007
17. Fabbri A, Santos A, Mezinska S, Mulinari S, Mintzes B. Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries. *Int J Health Policy Manag*. Jun 1 2018;7(6):504-509. doi:10.15171/ijhpm.2018.20



18. European Commission. Questions and Answers: Commission proposes an extension of the transitional periods for the application of the Medical Devices Regulation. Accessed 18 April, 2023. [https://ec.europa.eu/commission/presscorner/detail/en/qanda\\_23\\_24](https://ec.europa.eu/commission/presscorner/detail/en/qanda_23_24)
19. MedTech Europe. Members. Accessed 06 January, 2023. <https://www.medtecheurope.org/about-us/members/>
20. Johnson & Johnson. Annual Report 2019. Accessed 20 March, 2023. <https://www.investor.jnj.com/annual-meeting-materials/2019-annual-report>
21. Baxter International Inc. Annual Report. Accessed 20 March, 2023. [https://www.annualreports.co.uk/HostedData/AnnualReportArchive/b/NYSE\\_BAX\\_2019.pdf](https://www.annualreports.co.uk/HostedData/AnnualReportArchive/b/NYSE_BAX_2019.pdf)
22. MedTech Europe. Code of Ethical Business Practice. Accessed 04 February, 2022. <https://www.medtecheurope.org/resource-library/medtech-europe-code-of-ethical-business-practice/>
23. MedTech Europe. Transparent MedTech. Accessed 02 February, 2022. <https://www.ethicalmedtech.eu/transparent-medtech/>
24. MedTech Europe. Compliance Handbook. Accessed 14 March, 2023. [https://www.healthtechireland.ie/wp-content/uploads/2021/10/20211018\\_Compliance-Handbook\\_final.pdf](https://www.healthtechireland.ie/wp-content/uploads/2021/10/20211018_Compliance-Handbook_final.pdf)
25. Larkin J. Medical device industry payments to HCOs in Europe - protocol 04.02.22. Accessed 29 March, 2023. [https://osf.io/76jyh/?view\\_only=0e6088c19415407f91d8a473bbac21eb](https://osf.io/76jyh/?view_only=0e6088c19415407f91d8a473bbac21eb)
26. Central Bank of Ireland. Exchange Rates. Accessed 04 February, 2022. <https://www.centralbank.ie/statistics/interest-rates-exchange-rates/exchange-rates>
27. eurostat. First population estimates EU population up to over 513 million on 1 January 2019. Accessed 17 February, 2023. [https://ec.europa.eu/eurostat/documents/2995521/9967985/3-10072019-BP-EN.pdf/e152399b-cb9e-4a42-a155-c5de6dfe25d1#:~:text=With%2083.0%20million%20residents%20\(or,38.0%20million%2C%20r%207.4%25\)](https://ec.europa.eu/eurostat/documents/2995521/9967985/3-10072019-BP-EN.pdf/e152399b-cb9e-4a42-a155-c5de6dfe25d1#:~:text=With%2083.0%20million%20residents%20(or,38.0%20million%2C%20r%207.4%25))
28. World Bank. Russian Federation. Accessed 17 February, 2023. <https://data.worldbank.org/country/RU>
29. MedTech Europe. About us. Accessed 20 March, 2023. <https://www.medtecheurope.org/about-us/members/>
30. Johnson & Johnson Institute. AO Foundation. Accessed 11 March, 2023. <https://ijnjinstitute.com/en-ca/additional-resources/ao-foundation>
31. Twitter. OTC Foundation. Accessed 03 April, 2023. <https://twitter.com/OTCFoundation>
32. Empresite. Nubbecas Focused Solutions For Companies SL. - Madrid. Accessed 03 April, 2023. <https://empresite.eleconomista.es/NUBBECAS-FOCUSED-SOLUTIONS-FOR-COMPANIES.html>
33. cme4u. ABOUT cme4u. Accessed 03 April, 2023. <https://www.cme4u.org/index.php?lang=en&go=about>
34. Bloomberg. Avoris Retail Division SL. Accessed 03 April, 2023. <https://www.bloomberg.com/profile/company/6650608Z:SM?leadSource=uverify%20wall>
35. La Sociedad Española de Nefrología. Previous Congresses. Accessed 04 April, 2023. <https://www.senefro.org/modules.php?name=webstructure&idwebstructure=18>
36. Instituto de Investigación Sanitaria. Upcoming events. Accessed 04 April, 2023. <https://www.idisantiago.es/agenda-de-eventos/>
37. Sociedad Española de enfermería nefrológica. Events. Accessed 04 April, 2023. <https://www.seden.org/congresos>
38. MedTech Europe. Activity Report 2019. Accessed 10 March, 2023. <https://www.medtecheurope.org/wp-content/uploads/2020/04/Activity-Report-2019.pdf>
39. Arie S. The device industry and payments to doctors. *Bmj*. Dec 7 2015;351:h6182. doi:10.1136/bmj.h6182

40. Densford F. EU Medtech industry groups Eucomed, EDMA dissolve to form MedTech Europe. Accessed 04 January, 2023. <https://www.massdevice.com/eu-medtech-industry-groups-eucomed-edma-dissolve-form-medtech-europe/>
41. Eucomed. Transparency and Disclosure Interactions between Industry and Healthcare Professionals (HCP) Accessed 15 March, 2023. [http://www.medtecheurope.org/wp-content/uploads/2015/08/01112012\\_MTE\\_Transparency-and-Disclosure-Interactions-between-Industry-and-Healthcare-Professionals-HCP\\_Positionpaper\\_0.pdf](http://www.medtecheurope.org/wp-content/uploads/2015/08/01112012_MTE_Transparency-and-Disclosure-Interactions-between-Industry-and-Healthcare-Professionals-HCP_Positionpaper_0.pdf)
42. Ozieranski P, Martinon L, Jachiet PA, Mulinari S. Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe. *Int J Health Policy Manag.* Mar 15 2022;doi:10.34172/ijhpm.2022.6575
43. Centers for Medicare & Medicaid Services. The facts about Open Payments data. Accessed 16 March, 2023. <https://openpaymentsdata.cms.gov/summary>
44. Raspanti MS, Roberts DE, Bosick PGA. A Practitioner's Primer on the History and Use of the Federal Anti-Kickback Statute.
45. The Association of the British Pharmaceutical Industry. Disclosure UK. Accessed 14 March, 2023. <https://search.disclosureuk.org.uk/>
46. eurosfordocs. Country overview, 2017-2019. Accessed 31 March, 2023. <https://eurosfordocs.eu/public-dashboards/overview/>
47. Grundy Q, Habibi R, Shnier A, Mayes C, Lipworth W. Decoding disclosure: Comparing conflict of interest policy among the United States, France, and Australia. *Health Policy.* May 2018;122(5):509-518. doi:10.1016/j.healthpol.2018.03.015
48. Parker L, Karanges EA, Bero L. Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study. *BMJ Open.* Feb 19 2019;9(2):e024928. doi:10.1136/bmjopen-2018-024928
49. Zetterqvist AV, Merlo J, Mulinari S. Complaints, complainants, and rulings regarding drug promotion in the United Kingdom and Sweden 2004-2012: a quantitative and qualitative study of pharmaceutical industry self-regulation. *PLoS Med.* Feb 2015;12(2):e1001785. doi:10.1371/journal.pmed.1001785
50. Ozieranski P, Saito H, Rickard E, Mulinari S, Ozaki A. International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency. *Globalization and Health.* 2023/03/03 2023;19(1):14. doi:10.1186/s12992-022-00902-9
51. Seferidi P, Millett C, Lavery AA. Industry self-regulation fails to deliver healthier diets, again. *Bmj.* Jan 6 2021;372:m4762. doi:10.1136/bmj.m4762
52. Noel JK, Babor TF, Robaina K. Industry self-regulation of alcohol marketing: a systematic review of content and exposure research. *Addiction.* Jan 2017;112 Suppl 1:28-50. doi:10.1111/add.13410
53. Steinbrook R. Financial support of continuing medical education. *JAMA.* 2008;299(9):1060-1062.
54. O'Connell C. Pressure mounts to strip industry funding from continuing medical education programs. *Canadian Medical Association Journal.* 2010;182(17):E775.